2 Laws More Dangerous Than HIPAA for Patient Engagement

 Think HIPAA is your biggest hurdle in pharma marketing? Think again. In this episode of KLF Deep Dive, Darshan Kulkarni reveals why focusing solely on HIPAA leaves a massive, unregulated gap in your compliance strategy. We break down the "layered system" of risk—from aggressive state privacy laws and medical privacy statutes to the DOJ’s massive 2025 Bulk Data Rule. Whether you’re running patient engagement campaigns or leveraging marketing automation, you’ll learn why the tools you use to scale might be the very tools that trigger a regulatory audit. Don't leave your firm's reputation to a "narrow slice" of engagement. 

Transcript

Darshan 0:00

In pharma advertising, everyone asks the same question. Are we HIPAA compliant? And that question is necessary, but it's wildly incomplete. HIPAA covers a narrow slice of engagement. Most advertising, marketing, patient engagement, and lead generation sits outside that, and that's where the real risk comes in. Start with state law. Many states regulate health data far more broadly than HIPAA. If your marketing touches symptoms, conditions, treatment interest, or disease awareness, you may already be in regulated territory even if no provider is involved. Then layer on general state privacy laws. These laws treat health data as a sensitive personal data. This means consent rules, use limitations, and disclosure obligations that marketing teams often do not expect. I've dealt with clients who thought that being privacy compliant would be a small project, but this thing can balloon up depending on what you're trying to include and consider. Then add state medical privacy laws. Some states regulate medical privacy even when HIPAA does not apply. These laws catch pharma companies off guard because they apply to marketing and not care delivery.

SPEAKER_00 1:16

Enjoying our content? We'd love to hear more. Please like, comment, share, and find more.

Darshan 1:24

Then there's the bulk data rule. This came out of the DOJ in 2025. It's not coming from OCR, it's not coming from the places you'd normally look and expect. It applies to large-scale data collection, aggregation, and sharing of health data that is now under direct regulatory scrutiny. Size and scale increase risks fast, even when individual records may seem harmless. Then there are the do not contact lists. Ignoring internal or external suppression lists is not a minor mistake. It creates repeatable, documentable violations. That leads into TCP and CAN spam. Text messages, emails, patient outreach, and reminder campaigns can trigger liability based on how consent was collected, stored, and honored. Marketing automation breaks compliance faster than anything else. So make sure you're auditing your own marketing automation. And here's the bottom line. Privacy risk in advertising is not a single statute problem, it's a layered system problem. If your compliance strategy only focuses on HIPAA, you're missing most of the map, and regulators are very comfortable enforcing the parts that companies ignore. I look forward to hearing from you. Stay tuned for KLF Deep Dive. Call, click, or email.